Federal Agency · National Institutes of Health
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Posted October 15, 2024
Funding
Up to $250K
Closes
October 14, 2026
NAICS
541714
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity.
Award details
Award range: Up to $250K. Applications close on October 14, 2026 (169 days remaining).
Categories
Not categorized
Sign up at GrantRegister to see if this grant matches your organization.
Match my organization →View application on Grants.gov →·Source: Grants.gov·Last seen Apr 28, 2026